Currently, the treatment of CKD includes symptomatic treatment with renin‐angiotensin‐aldosterone system (RAAS) drugs, sodium‐glucose cotransporter protein 2 (SGLT2) inhibitors, and immunosuppressants to improve proteinuria, hypertension, and hyperglycemia, and to slow down the progression of CKD (Lazzaroni et al. 2022; Maringhini and Zoccali 2024). This evidence concerns the gene SLC5A2 and chronic kidney disease.